Psoriasis

Novel biologics are moving into off-label indications to expand the dermatologic armamentarium for a broad range of inflammatory skin diseases.

A new study shows a possible association between fasting and skin improvement in psoriasis patients.

Psoriasis patients may have a higher risk of contracting COVID-19, according to study results recently presented at AAD VMX 2021.

Research presented at the EADV Spring Symposium 2021 investigated the link between gut bacteria and skin inflammation.

After data from a phase 3 study, FDA opens potential for apremilast to be the first and only approved oral therapy for mild to moderate plaque psoriasis.

Mark Lebwohl, MD, discusses his recent presentation from AAD VMX 2021 regarding new data for various biologics for the treatment of psoriasis.

Study findings show calcipotriene-betamethasone foam to be safe and moderately effective in skin of color patients with psoriasis but failed to meet several secondary endpoints and to demonstrate statistically significant changes.

Deucravacitinib meets primary end points for treating moderate to severe psoriasis.

The FDA has set a Prescription Drug User Fee Act (PDUFA) date for bimekizumab (UCB) for the treatment of psoriasis.

Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.

In phase 3b data presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021 showed bimekizumab achieved superior levels of complete skin clearance compared to secukinumab for psoriasis.

Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.

Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.

New data on the safety and efficacy of roflumilast foam (ARQ-154, Arcutis Biotherapeutics) for scalp and body psoriasis was presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 2021.

A study finds low risk of malignancy from secukinumab treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis patients, despite limited data.

AbbVie announces the submission of regulatory filings for risankizumab to the FDA and EMA seeking approval for the drug as a treatment for psoriatic arthritis.

A study found psoriasis patients treated with biologic therapy had a significant reduction in high-risk plaque in heart arteries over 1 year.

A new study in Arthritis Care & Research found depression and anxiety reduces the possibility of achieving minimal disease activity in patients with psoriatic arthritis.

Sun Pharmaceuticals announces the publication of results from its 5-year extension studies evaluating the safety, efficacy and tolerability of tildrakizumab-asmn.

Pre- and postmarketing psoriasis studies support novel drug results and new labeling.

Dermavant announces positive results from an interim analysis of its PSOARING 3 safety study investigating tapinarof cream 1% for the treatment of plaque psoriasis in adult patients.

According to one expert, recently completed phase 3 trials of novel drugs have shown impressive results, with 2021 expected to be an exciting year that will bring further advances in treatment options for patients with moderate-to-severe plaque psoriasis.

New AAD-NPF guidelines focus on biologics, topical therapy, systemic non-biological therapies, management of pediatric patients, use of phototherapy and comorbidities.

A proprietary food supplement designed to balance the gut microbiome and target the over production of skin cells will be examined in an upcoming consumer study that has recently announced participant enrollment.

Safety profiles remain consistent longer-term but cost and accessibility are major challenges for biologics aimed at treating psoriasis.

Several systemic therapies are available for the treatment of patients with moderate to severe psoriasis. Continued research has further elucidated the immunopathogenesis of the disease, leading to the development of novel biologic agents that are proving to more effectively and safely address moderate to severe psoriatic lesions.

According to a study conducted by Galderma, both rosacea and psoriasis have a significant QOL impact on patients, with a proportion of patients reporting feelings of anxiety and depression due to their disease.

Genetic polymorphisms may increase psoriasis susceptibility, according to a study that found patients who have the G allele in the JAK1 gene have twice the risk of developing psoriasis, and for those with the JAK3 allele, the risk rises nearly 2-fold.

Studies confirm improvement achieved and maintained through one year of active treatment with similar scores for patients switching from placebo to guselkumab.

Ixekizumab demonstrated long-term efficacy in treating psoriasis and psoriatic arthritis across five years, according to data presented by Eli Lilly at the 29th annual European Academy of Dermatology and Venereology (EADV) Congress.